Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Özkan, Yalkinoglu"'
Autor:
Maria Pitsiu, Özkan Yalkinoglu, Colm Farrell, Pascal Girard, Cristina Vazquez‐Mateo, Orestis Papasouliotis
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 8, Pp 1157-1169 (2023)
Abstract B cell stimulating factor (BLyS) and a proliferation‐inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that blocks BLyS and APRI
Externí odkaz:
https://doaj.org/article/9efaa86ce0bd41dbb6749afefe027a5e
Autor:
Xiaoyan Yin, Ying Li, Wilhelmina Bagchus, Özkan Yalkinoglu, Deon Bezuidenhout, Aliona Tappert, James McCarthy, Louise Marquart, Claude Oeuvray
Publikováno v:
Malaria Journal, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Background Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clea
Externí odkaz:
https://doaj.org/article/f06f350695e94c21af64078bdc6defd9
Autor:
Akash Khandelwal, Francisca Arez, Paula M. Alves, Lassina Badolo, Catarina Brito, Christoph Fischli, Diana Fontinha, Claude Oeuvray, Miguel Prudêncio, Matthias Rottmann, Justin Wilkins, Özkan Yalkinoglu, Wilhelmina M. Bagchus, Thomas Spangenberg
Publikováno v:
Malaria Journal, Vol 21, Iss 1, Pp 1-7 (2022)
Abstract Background Targeting the asymptomatic liver stage of Plasmodium infection through chemoprevention could become a key intervention to reduce malaria-associated incidence and mortality. Methods M5717, a Plasmodium elongation factor 2 inhibitor
Externí odkaz:
https://doaj.org/article/1a184acca8e44dcf9fd53edb5f8e0845
Autor:
Workineh Shibeshi, Wilhelmina Bagchus, Özkan Yalkinoglu, Aliona Tappert, Ephrem Engidawork, Claude Oeuvray
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background The development of novel malaria vaccines and antimalarial drugs is limited partly by emerging challenges to conduct field trials in malaria endemic areas, including unknown effects of existing immunity and a reported fall in mala
Externí odkaz:
https://doaj.org/article/62bb7a733c2747f7a2c07f158e7cf59c
Autor:
Mahya Eslami, Daniela Willen, Orestis Papasouliotis, Sonia Schuepbach-Mallpell, Laure Willen, Olivier Donzé, Özkan Yalkinoglu, Pascal Schneider
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BAFF (B cell activation factor of the TNF family/B lymphocyte stimulator, BLyS) and APRIL (a proliferation-inducing ligand) are targeted by atacicept, a decoy receptor consisting of the extracellular domain of TACI (transmembrane activator and calciu
Externí odkaz:
https://doaj.org/article/9e52c1302a504221b6764fbf467e5860
Autor:
Mahya Eslami, Edgar Meinl, Hermann Eibel, Laure Willen, Olivier Donzé, Ottmar Distl, Holm Schneider, Daniel E. Speiser, Dimitrios Tsiantoulas, Özkan Yalkinoglu, Eileen Samy, Pascal Schneider
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
B cell activation factor of the TNF family (BAFF/BLyS), an essential B cell survival factor of which circulating levels are elevated in several autoimmune disorders, is targeted in the clinic for the treatment of systemic lupus erythematosus (SLE). T
Externí odkaz:
https://doaj.org/article/76027ff55cba448a9c4dc593f4326ad2
Publikováno v:
Frontiers in Endocrinology, Vol 8 (2018)
This was a Phase I, open-label, randomized, two-period, two-sequence crossover study [ClinicalTrials.gov NCT02317809 (https://www.clinicaltrials.gov/ct2/show/NCT02317809); EudraCT 2014-003506-32] assessing the bioequivalence of the liquid and freeze-
Externí odkaz:
https://doaj.org/article/e2aa39cb8fcc48e2bf6f522754c68205
Autor:
Louise Marquart, Lachlan Webb, James S. McCarthy, Claude Oeuvray, David A. Fidock, Xiaoyan Yin, Anand Odedra, Satish K. Dhingra, Deon Bezuidenhout, Akash Khandelwal, Aliona Tappert, Özkan Yalkinoglu, Marla J. Giddins, Wilhelmina M Bagchus, Rebecca Webster
Publikováno v:
The Lancet. Infectious Diseases
Summary Background M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an antimalarial. We aimed to characterise the safety, pharmacokinetics, and antimalarial activity of M5717 in healthy voluntee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74eadc3ee9e4fdaa8eb7a13120f35214
https://doi.org/10.1016/s1473-3099(21)00252-8
https://doi.org/10.1016/s1473-3099(21)00252-8
Autor:
Deon Bezuidenhout, Mamadou Ouattara, Elly Kourany-Lefoll, Eliézer K. N’Goran, Eric Huber, Brooke Hayward, Özkan Yalkinoglu, N. A. David Aka, Aliona Tappert, Xiaoyan Yin, Wilhelmina Bagchus
Publikováno v:
Frontiers in Tropical Diseases. 2
IntroductionTwo novel formulations of praziquantel (PZQ) and Levo-(L-)PZQ (arpraziquantel) have been developed for the treatment of schistosomiasis in preschool-age children and infants.MethodsThis open-label, dose-finding Phase 2 study assessed the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d4f9cdf5c940c18c4b62789326d2c60
https://doi.org/10.3389/fitd.2021.679373
https://doi.org/10.3389/fitd.2021.679373
Autor:
Michele Vigolo, Christine Kowalczyk-Quintas, Özkan Yalkinoglu, Daniela Willen, Mahya Eslami, Benjamin Peter, Eileen Samy, Michaela Golob, Pascal Schneider, Hervé Broly, Laure Willen, Sonia Schuepbach-Mallepell
Publikováno v:
British journal of pharmacology, vol. 176, no. 20, pp. 4019-4033
British Journal of Pharmacology
British Journal of Pharmacology
Background and Purpose The TNF family ligands, B cell activating factor of the TNF family (BAFF, also known as B lymphocyte stimulator, BLyS) and a proliferation‐inducing ligand (APRIL), share the transmembrane activator and calcium‐modulator and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654b0584a5fc1a11e6e8c6ea08f6e7e7
https://doi.org/10.1111/bph.14811
https://doi.org/10.1111/bph.14811